G3BP2-Tau Interaction Modulators for Tauopathy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Tau-associated diseases, such as Alzheimer's and frontotemporal dementia, are limited due to a lack of understanding of the underlying mechanisms, necessitating the identification of new target proteins for effective therapies.
Innovation Solution
Administering a compound that modulates the protein-protein interaction between a protein with an NTF2-like domain, specifically the G3BP2 protein, and the Tau protein to enhance or mimic their interaction, thereby treating Tau-associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for Tau-associated diseases are used, then existing therapeutic options are maintained, but treatment effectiveness is limited due to lack of understanding of underlying mechanisms
Solution Approach 1:
The patent introduces G3BP2 as an intermediary protein that mediates between Tau aggregation and cellular stress response pathways. By identifying G3BP2 as a binding partner of Tau that regulates stress granule formation and Tau aggregation, the patent provides a molecular mediator that connects Tau pathology to cellular responses, enabling more targeted and effective treatments for Tau-associated diseases
2Reliability
If new target proteins are identified to improve treatment effectiveness, then therapeutic options are expanded, but device and method complexity increases
Solution Approach 1:
The patent segments the complex Tau-associated disease pathology into distinct molecular interactions and pathways, specifically identifying the G3BP2-Tau interaction as a separable target. By focusing on this specific protein-protein interaction and its role in stress granule formation, the patent breaks down the overall disease mechanism into manageable components that can be targeted by specific therapeutic interventions
Solution Approach 2:
G3BP2 serves as a tractable intermediary target that connects Tau aggregation to cellular stress responses. Rather than directly targeting complex Tau aggregates or downstream neurodegeneration, the patent identifies G3BP2 as an accessible molecular target that mediates these processes, simplifying the therapeutic approach while maintaining effectiveness
Data Source
AI summary
Provided are methods for the treatment of a Tau associated disease, comprising administering to a subject an effective amount of a compound modulating a protein-protein interaction between a protein comprising a NTF2-like domain having the amino acid sequence set forth as SEQ ID NO: 3 and Tau protein.